| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yvonne Flores | |
| Lenin Pavón | |||
| Gabriela Hurtado-Alvarado | |||
| Enrique Becerril-Villanueva | |||
| Gilberto Pérez-Sánchez | |||
| José Luis Maldonado-García | |||
| Oscar Medina-Contreras | |||
| Raúl Escamilla | |||
| Ricardo Saracco | |||
| Samantha Alvarez-Herrera | |||
| P2860 | cites work | Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders | Q21129108 |
| Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes | Q21144599 | ||
| Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis | Q24606868 | ||
| Aripiprazole for autism spectrum disorders (ASD) | Q26471439 | ||
| Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis | Q26828452 | ||
| Aripiprazole, alcohol and substance abuse: a review | Q26866003 | ||
| Immunomodulatory Effects Mediated by Dopamine | Q28071580 | ||
| Immunomodulatory effects mediated by serotonin | Q28084203 | ||
| Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | Q28293647 | ||
| Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects | Q28657600 | ||
| Clinical utility of the risperidone formulations in the management of schizophrenia | Q30429721 | ||
| Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. | Q30459096 | ||
| New atypical antipsychotics for schizophrenia: iloperidone | Q30482195 | ||
| Ziprasidone decreases cortisol excretion in healthy subjects | Q30498400 | ||
| A case report of olanzapine-induced hypersensitivity syndrome | Q32058502 | ||
| Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study | Q33186211 | ||
| In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). | Q33370164 | ||
| Quetiapine-induced leucopenia and thrombocytopenia | Q33377744 | ||
| The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. | Q33619940 | ||
| Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt | Q33764262 | ||
| Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study | Q33810051 | ||
| Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds | Q33929303 | ||
| Teaching old receptors new tricks: biasing seven-transmembrane receptors | Q33985759 | ||
| Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 | ||
| Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine | Q33995754 | ||
| Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis | Q34035137 | ||
| Clinical pharmacokinetics of quetiapine: an atypical antipsychotic | Q34087233 | ||
| Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity | Q34110921 | ||
| Ziprasidone-induced galactorrhea in an adolescent female: a case report | Q34163645 | ||
| Antipsychotics in pediatric and adolescent patients: a review of comparative safety data | Q34190469 | ||
| Maintenance therapies in bipolar disorders | Q34268760 | ||
| Paliperidone: a review of clinical trial data and clinical implications | Q34321924 | ||
| Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder | Q34333899 | ||
| Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor | Q34376884 | ||
| Amelioration of experimental autoimmune encephalomyelitis by clozapine is not associated with defective CD4 T cell responses. | Q37728642 | ||
| Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY. | Q37735342 | ||
| Hyperprolactinaemia during treatment with paliperidone | Q37739435 | ||
| Metabolic syndrome with the atypical antipsychotics | Q37780660 | ||
| The role of serotonin receptors in the action of atypical antipsychotic drugs | Q37855189 | ||
| Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis | Q37873034 | ||
| Metabolic and cardiovascular adverse effects associated with antipsychotic drugs | Q37947095 | ||
| Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review | Q37960632 | ||
| Risperidone-induced leukopenia: a case report and brief review of literature | Q38004186 | ||
| Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review | Q38005470 | ||
| Critical review of antipsychotic polypharmacy in the treatment of schizophrenia | Q38020263 | ||
| A review of olanzapine pamoate | Q38022638 | ||
| New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. | Q38044984 | ||
| Update on typical and atypical antipsychotic drugs | Q38047415 | ||
| A review of paliperidone palmitate | Q38067137 | ||
| Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults | Q38070179 | ||
| Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine | Q38132163 | ||
| Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. | Q38160607 | ||
| Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole | Q38174144 | ||
| Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis | Q38202392 | ||
| Asenapine review, part II: clinical efficacy, safety and tolerability | Q38209081 | ||
| Antipsychotic treatment in breast cancer patients | Q38216317 | ||
| Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis | Q38258215 | ||
| BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis | Q38305240 | ||
| Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study | Q38374807 | ||
| Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis | Q38398066 | ||
| Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics | Q38500850 | ||
| Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis. | Q38545272 | ||
| Neurotrophins and B-cell malignancies | Q38591883 | ||
| Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine. | Q38712962 | ||
| Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats | Q38735631 | ||
| Comparative Physicochemical and Pharmacokinetic Properties of Quetiapine and Its Active Metabolite Norquetiapine | Q38800625 | ||
| Haloperidol and Risperidone at high concentrations activate an in vitro inflammatory response of RAW 264.7 macrophage cells by induction of apoptosis and modification of cytokine levels | Q38833783 | ||
| Depot risperidone-induced adverse metabolic alterations in female rats. | Q38873420 | ||
| Effectiveness of long-acting paliperidone palmitate in borderline personality disorder | Q38979088 | ||
| Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis | Q85375082 | ||
| Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia | Q47194564 | ||
| Weight gain in risperidone therapy: investigation of peripheral hypothalamic neurohormone levels in psychotic patients | Q47226459 | ||
| A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients | Q47242918 | ||
| Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic | Q47249016 | ||
| Psychiatric Patients with Antipsychotic Drug-Induced Hyperprolactinemia and Menstruation Disorders | Q47255628 | ||
| Effect of clozapine dose and concentration on fasting concentration of appetite regulating peptides | Q47257698 | ||
| The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study | Q47302269 | ||
| From the Promiscuous Asenapine to Potent Fluorescent Ligands Acting at a Series of Aminergic G-Protein-Coupled Receptors | Q47315901 | ||
| Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters | Q47332928 | ||
| Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone | Q47350555 | ||
| Weight gain and ghrelin level after olanzapine monotherapy | Q47394922 | ||
| A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients. | Q47582755 | ||
| A Review of Asenapine in the Treatment of Bipolar Disorder | Q47724110 | ||
| Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha | Q47730945 | ||
| Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission. | Q47741137 | ||
| The central mechanism of risperidone-induced hyperprolactinemia | Q47768124 | ||
| Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders | Q47806978 | ||
| Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine | Q47931115 | ||
| Effect of Adjunctive Aripiprazole on Sexual Dysfunction in Schizophrenia: A Preliminary Open-Label Study | Q47931408 | ||
| Changes in the cytokine profile in first-episode, drug-naïve patients with psychosis after short-term antipsychotic treatment | Q47946881 | ||
| Increased high-sensitivity C-reactive protein levels in Taiwanese schizophrenic patients | Q48000662 | ||
| Kounis syndrome and ziprasidone. | Q48020598 | ||
| Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population | Q48026160 | ||
| Associations of fatty acids with cognition, psychopathology, and brain-derived neurotrophic factor levels in patients with first-episode schizophrenia and related disorders treated with paliperidone extended release | Q48097552 | ||
| Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial | Q48201230 | ||
| Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. | Q48215288 | ||
| The Role of Neurotrophins in Inflammation and Allergy | Q48302244 | ||
| Human neutrophils show decreased survival upon long-term exposure to clozapine. | Q48340851 | ||
| Antipsychotics influence Toll-like receptor (TLR) expression and its relationship with cognitive functions in schizophrenia. | Q48387210 | ||
| Effects of risperidone treatment on the expression of hypothalamic neuropeptide in appetite regulation in Wistar rats | Q48435093 | ||
| Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). | Q48555093 | ||
| Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder | Q48912979 | ||
| Radioreceptor binding profile of the atypical antipsychotic olanzapine | Q49130929 | ||
| Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion: A case report | Q50003034 | ||
| Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers | Q50083713 | ||
| Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia | Q50151947 | ||
| Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects | Q50174817 | ||
| Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms. | Q50452964 | ||
| Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. | Q50575257 | ||
| Quetiapine treatment in youth is associated with decreased insulin secretion. | Q50654557 | ||
| Activation of Th17 cells in drug naïve, first episode schizophrenia. | Q50664388 | ||
| Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. | Q50687337 | ||
| Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia. | Q50759774 | ||
| Hyperprolactinemia with aripiprazole: understanding the paradox. | Q50768045 | ||
| The Ireland-Claisen rearrangement strategy towards the synthesis of the schizophrenia drug, (+)-asenapine. | Q50903078 | ||
| Parasympathetic vasoactive intestinal peptide (VIP): a likely contributor to clozapine-induced sialorrhoea. | Q50942047 | ||
| Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version). | Q50955502 | ||
| Elevated risperidone serum concentrations during acute inflammation, two cases. | Q50973731 | ||
| Effect of antipsychotics on mitochondrial bioenergetics of rat ovarian theca cells. | Q51092571 | ||
| Bone loss associated with hyperprolactinemia in patients with schizophrenia. | Q51274832 | ||
| Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. | Q34403529 | ||
| Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques | Q34413021 | ||
| Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study | Q34519627 | ||
| Ziprasidone metabolism, aldehyde oxidase, and clinical implications | Q34534880 | ||
| Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. | Q34590921 | ||
| Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years | Q34597411 | ||
| Aripiprazole in schizophrenia and schizoaffective disorder: A review | Q34616681 | ||
| Almost all antipsychotics result in weight gain: a meta-analysis | Q34661499 | ||
| Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers | Q34665858 | ||
| Change in plasma cytokine levels during risperidone treatment in children with autism | Q34719440 | ||
| Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. | Q34925193 | ||
| Quetiapine in the treatment of schizophrenia and related disorders | Q34965927 | ||
| Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity | Q35000419 | ||
| Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat | Q35004010 | ||
| Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms | Q35014069 | ||
| Aripiprazole: profile on efficacy and safety | Q35020547 | ||
| Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone | Q35024279 | ||
| Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. | Q35038921 | ||
| Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic | Q35094691 | ||
| Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate | Q35100107 | ||
| Current status of antipsychotic treatment | Q35137427 | ||
| Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. | Q35179022 | ||
| GLP-1 based therapeutics: simultaneously combating T2DM and obesity. | Q35200252 | ||
| Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis | Q35566086 | ||
| Muscarinic mechanisms of antipsychotic atypicality | Q35595252 | ||
| Clinical pharmacology of atypical antipsychotics: an update. | Q35728228 | ||
| Immunotoxicological Effects of Aripiprazole: In vivo and In vitro Studies | Q35843979 | ||
| The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factors | Q35864617 | ||
| Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure | Q35921844 | ||
| The role of paliperidone extended release for the treatment of bipolar disorder | Q35939680 | ||
| Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia | Q35941055 | ||
| Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report | Q36031124 | ||
| Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial | Q36136886 | ||
| Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry | Q36152491 | ||
| Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review | Q36186039 | ||
| Ziprasidone induces cytotoxicity and genotoxicity in human peripheral lymphocytes | Q39148095 | ||
| The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies. | Q39151379 | ||
| Signaling bias in drug discovery | Q39170901 | ||
| Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: A meta-analysis | Q39174583 | ||
| Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment | Q39242341 | ||
| Atypical antipsychotics such as risperidone, but not paliperidone, worsen vascular endothelial function via upregulation of adhesion molecules VCAM-1, ICAM-1, and E-selectin in diabetic rats | Q39304810 | ||
| Leukopenia Associated with Risperidone Treatment | Q39338752 | ||
| Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients | Q39379081 | ||
| Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. | Q39399262 | ||
| Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation | Q39436079 | ||
| A case of acute pancreatitis associated with risperidone treatment | Q39659530 | ||
| Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample | Q39859959 | ||
| Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. | Q39931036 | ||
| Effects of quetiapine, risperidone, 9-hydroxyrisperidone and ziprasidone on the survival of human neuronal and immune cells in vitro | Q39945932 | ||
| 9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder | Q39995440 | ||
| Role of cytokine changes in clozapine-induced fever: A cohort prospective study | Q40072330 | ||
| Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects | Q40195883 | ||
| Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile | Q40785107 | ||
| Risperidone-induced reversible neutropenia | Q41183689 | ||
| Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels | Q41191596 | ||
| Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats | Q41598047 | ||
| Cell contact-dependent functional selectivity of β2-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation | Q41790957 | ||
| Role of sublingual asenapine in treatment of schizophrenia | Q41822209 | ||
| Quetiapine attenuates glial activation and proinflammatory cytokines in APP/PS1 transgenic mice via inhibition of nuclear factor-κB pathway | Q41827827 | ||
| Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures | Q41883047 | ||
| Haloperidol affects bones while clozapine alters metabolic parameters - sex specific effects in rats perinatally treated with phencyclidine | Q42375259 | ||
| Evidence for Hypothalamus-Pituitary-Adrenal Axis and Immune Alterations at Prodrome of Psychosis in Males. | Q42376224 | ||
| Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. | Q42509964 | ||
| Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis. | Q42907238 | ||
| Electroanalytical characteristics of antipsychotic drug ziprasidone and its determination in pharmaceuticals and serum samples on solid electrodes. | Q42946420 | ||
| Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients | Q42973933 | ||
| Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients | Q43107440 | ||
| Hyperprolactinaemia - a risperidone side-effect | Q43122627 | ||
| Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients | Q43135416 | ||
| Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics | Q43135417 | ||
| Neutropenia induced by second generation antipsychotics: a prospective investigation | Q43154460 | ||
| Olanzapine-induced eosinophilic pleuritis | Q43182884 | ||
| Can quetiapine-induced hypothyroidism be reversible without quetiapine discontinuation? | Q43263653 | ||
| Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour | Q43292362 | ||
| Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine | Q43662228 | ||
| Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia | Q43680545 | ||
| Acute neutropenia in a patient treated with quetiapine | Q43701779 | ||
| Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders | Q43828278 | ||
| Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone | Q44000143 | ||
| Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 | ||
| Risperidone/paliperidone induced neutropenia and lymphopenia | Q44211071 | ||
| Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. | Q44254015 | ||
| Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors | Q44485883 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Toxic rise of clozapine plasma concentrations in relation to inflammation | Q44574549 | ||
| The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study | Q44627462 | ||
| Regulation of macrophage immune responses by antipsychotic drugs | Q44755614 | ||
| Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers | Q44821225 | ||
| Neuroendocrine effects of quetiapine in healthy volunteers | Q45094377 | ||
| Ziprasidone-induced galactorrhea: a case report | Q45278890 | ||
| Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies | Q45786828 | ||
| Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia | Q46110645 | ||
| Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. | Q46152573 | ||
| Ziprasidone, a second-generation antipsychotic drug, triggers a macrophage inflammatory response in vitro | Q46268676 | ||
| Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. | Q46331351 | ||
| The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro. | Q46577550 | ||
| Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia | Q46867916 | ||
| The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects | Q46908282 | ||
| Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome | Q47152270 | ||
| Risperidone-Induced Amenorrhea in Floridly Psychotic Female | Q47158601 | ||
| Borderline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment | Q36254513 | ||
| Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics | Q36301864 | ||
| Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia | Q36310008 | ||
| Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence | Q36389699 | ||
| Asenapine in bipolar I disorder: evidence and place in patient management | Q36515504 | ||
| Paliperidone: quo vadis? | Q36753737 | ||
| Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial | Q36756154 | ||
| Quetiapine: a review of its use in the treatment of bipolar depression | Q36815093 | ||
| Iloperidone binding to human and rat dopamine and 5-HT receptors | Q36842371 | ||
| Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder | Q36853567 | ||
| Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder | Q36938311 | ||
| Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder | Q36997248 | ||
| Haematological toxicity of drugs used in psychiatry | Q37039855 | ||
| Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children | Q37058619 | ||
| Paliperidone for treatment of schizophrenia | Q37076321 | ||
| Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment | Q37078982 | ||
| Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion. | Q37120751 | ||
| Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials | Q37137001 | ||
| Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one | Q37147674 | ||
| Clozapine reinitiation following a "red result" secondary to chemotherapy | Q37160727 | ||
| A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | Q37172973 | ||
| Prolactin Levels After Switching to Paliperidone Palmitate in Patients with Schizophrenia | Q37361982 | ||
| Supra-therapeutic plasma concentrations of haloperidol induce moderate inhibition of lipopolysaccharide-induced interleukin-8 release in human monocytes | Q37410987 | ||
| A case with neutropenia related with the use of various atypical antipsychotics | Q37516098 | ||
| Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis | Q37615022 | ||
| Risperidone Induced Granulomatous Mastitis Secondary to Hyperprolactinemia in a Non-Pregnant Woman-A Rare Case Report in a Bipolar Disorder | Q37663643 | ||
| Atypical antipsychotics: recent research findings and applications to clinical practice: Proceedings of a symposium presented at the 29th Annual European College of Neuropsychopharmacology Congress, 19 September 2016, Vienna, Austria | Q37698621 | ||
| Regulation of neutrophil phagocytosis of Escherichia coli by antipsychotic drugs | Q86108571 | ||
| Pancreatic Endocrine Effects of Dopamine Receptors in Human Islet Cells | Q87224193 | ||
| Quetiapine XR-induced neutropenia: is a clozapine trial still possible for treatment-resistant schizophrenia? A case report | Q87580171 | ||
| Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia | Q87884826 | ||
| Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction? | Q87976031 | ||
| Clozapine-Induced DRESS Syndrome: A Case Series From the AMSP Multicenter Drug Safety Surveillance Project | Q88098972 | ||
| Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis | Q88161215 | ||
| Aripiprazole-Induced Neutropenia: Case Report and Literature Review | Q88532032 | ||
| [The effect of antipsychotic drug on monoamine receptors in peripheral blood mononuclear cells: affinity linked mechanism] | Q88556347 | ||
| Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia | Q88959291 | ||
| Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial | Q89136911 | ||
| Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naïve first episode psychosis individuals: A 3 months randomized study | Q89238866 | ||
| Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences | Q89313952 | ||
| Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects | Q89329442 | ||
| Antipsychotics and glucose metabolism: how brain and body collide | Q89403300 | ||
| Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain? | Q89599823 | ||
| The development of antipsychotic drugs | Q90285776 | ||
| Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine | Q90351634 | ||
| Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives | Q90356648 | ||
| Clozapine, ziprasidone, and sertindole-induced morphological changes in the rat heart and their relationship to antioxidant enzymes function | Q90413169 | ||
| Safety of a Clozapine Trial Following Quetiapine-Induced Leukopenia: A Case Report | Q90800134 | ||
| Acute agranulocytosis when switching from risperidone to paliperidone | Q91016511 | ||
| An Ex Vivo Fermentation Screening Platform to Study Drug Metabolism by Human Gut Microbiota | Q91208962 | ||
| Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells | Q91451177 | ||
| Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder | Q91560107 | ||
| Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons | Q91790829 | ||
| Summary of the clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults | Q91875731 | ||
| Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons | Q91893300 | ||
| Psychotropics and the Microbiome: a Chamber of Secrets… | Q91925617 | ||
| Paliperidone Long-Acting Injections in Huntington's Disease for Motor and Behavioural Disturbances | Q91960572 | ||
| Paliperidone Use in Child Psychiatry: Evidence or Diffidence? | Q92079685 | ||
| The role of oxidative stress in ovarian toxicity induced by haloperidol and clozapine-a histological and biochemical study in albino rats | Q92160667 | ||
| A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models | Q92204644 | ||
| Hyperprolactinemia in psychotic patients treated in monotherapy with long-acting injectable antipsychotics | Q92225966 | ||
| Appetite regulating hormones in first-episode psychosis: A systematic review and meta-analysis | Q92242697 | ||
| Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand | Q92270326 | ||
| Galactorrhea Induced by Risperidone | Q92321125 | ||
| Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: A case report | Q92391555 | ||
| PROLACTIN LEVEL IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA TREATED FOR ONE YEAR WITH ATYPICAL ANTIPSYCHOTICS | Q92432650 | ||
| Polypharmacy in schizophrenia | Q92458968 | ||
| Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review | Q92626334 | ||
| Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting | Q92629891 | ||
| Olanzapine-Induced Hyperprolactinemia: Two Case Reports | Q92649533 | ||
| Insulin Resistance in Schizophrenia | Q92664886 | ||
| Psychotropic Medication for Children and Adolescents with Eating Disorders | Q92828684 | ||
| Pharmacological management of delusions associated with dementia | Q92864478 | ||
| Risperidone Induced Isolated Thrombocytopenia: A Rare Adverse Event | Q94010466 | ||
| Risperidone-induced acute eosinophilic pneumonia | Q95416686 | ||
| Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. | Q51276241 | ||
| Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine. | Q51349981 | ||
| Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. | Q51358582 | ||
| Impact of antipsychotics on cytokine production in-vitro. | Q51461858 | ||
| The histamine H4 receptor modulates the differentiation process of human monocyte-derived M1 macrophages and the release of CCL4/MIP-1β from fully differentiated M1 macrophages. | Q51730629 | ||
| Urticaria and angio-oedema due to ziprasidone. | Q51756293 | ||
| Leukopenia and neutropenia induced by quetiapine. | Q51789358 | ||
| Ziprasidone-associated pedal edema in the treatment of schizophrenia. | Q51809768 | ||
| Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. | Q52306647 | ||
| Classics in Chemical Neuroscience: Risperidone. | Q52563209 | ||
| Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro. | Q53035030 | ||
| Hyperprolactinaemia in first episode psychosis - A longitudinal assessment. | Q53101828 | ||
| Increase in white cell and neutrophil counts during the first eighteen weeks of treatment with clozapine in patients admitted to a long-term psychiatric care inpatient unit. | Q53104597 | ||
| Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. | Q53202972 | ||
| 5-HT(1B) receptors play a prominent role in the proliferation of T-lymphocytes. | Q53596217 | ||
| Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. | Q53788748 | ||
| Potentiating and synergistic effect of grapefruit juice on the antioxidant and anti-inflammatory activity of aripiprazole against hydrogen peroxide induced oxidative stress in mice. | Q54119984 | ||
| Antipsychotic drug-associated gene-miRNA interaction in T-lymphocytes. | Q54225210 | ||
| Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets. | Q54573954 | ||
| Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota. | Q54920392 | ||
| Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis. | Q54959236 | ||
| Stearoyl-CoA desaturase-1 promotes colorectal cancer metastasis in response to glucose by suppressing PTEN. | Q55212706 | ||
| Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. | Q55232340 | ||
| Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia | Q56979461 | ||
| Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function | Q57098990 | ||
| A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics | Q57471391 | ||
| Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring - the effect of antipsychotic drugs | Q60445730 | ||
| Prolactin levels in risperidone treatment of first-episode schizophrenia | Q60620480 | ||
| Changes in Serum Levels of Brain Derived Neurotrophic Factor and Nerve Growth Factor-Beta in Schizophrenic Patients Before and After Treatment | Q60629601 | ||
| Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone | Q60633110 | ||
| Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis | Q60641837 | ||
| Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance | Q61798233 | ||
| Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome | Q61943520 | ||
| Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis | Q62722210 | ||
| A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia | Q64062364 | ||
| Effects of olanzapine on cytokine profile and brain-derived neurotrophic factor in drug-naive subjects with first-episode psychosis | Q64271436 | ||
| Variability of peripheral blood lymphocyte beta-2-adrenergic receptor density in humans | Q74363506 | ||
| Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia | Q78170727 | ||
| Aripiprazole | Q78382372 | ||
| Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects | Q79226756 | ||
| Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls | Q82702319 | ||
| Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils | Q82874747 | ||
| Metabolism and excretion of asenapine in healthy male subjects | Q82994979 | ||
| Neutropenia during risperidone treatment | Q83200097 | ||
| Clozapine inhibits Th1 cell differentiation and causes the suppression of IFN-γ production in peripheral blood mononuclear cells | Q83304588 | ||
| Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol | Q84511203 | ||
| Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release | Q84512128 | ||
| Paliperidone-induced leukopenia and neutropenia: A case report | Q85155375 | ||
| Pityriasis rosea-like drug reaction to asenapine | Q85196914 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P304 | page(s) | 195 | |
| P577 | publication date | 2020-04-21 | |
| P1433 | published in | Frontiers in Endocrinology | Q27723680 |
| P1476 | title | Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics | |
| P478 | volume | 11 |
Search more.